Karuna Therapeutics, Inc., a Bristol Myers Squibb Company
Clinical trials sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb Company, explained in plain language.
A subsidiary of Bristol Myers Squibb, focused on developing treatments for psychiatric and neurological disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Hope for Alzheimer's psychosis: new drug aims to stop relapses Results expected Oct 2026 (estimated)
- Hope for Alzheimer's psychosis: new drug KarXT enters final trial Results expected Nov 2026 (estimated)
- Can Anti-Nausea meds tame KarXT's stomach woes? Results expected Nov 2026 (estimated)
- Gene type may change how KarXT works in your body Results expected Dec 2026 (estimated)
- Could this pill ease Alzheimer's hallucinations? Results expected Dec 2026 (estimated)
-
New drug aims to keep schizophrenia in check
Disease control Recruiting nowThis phase 3 trial tests whether KarXT (a combination of xanomeline and trospium chloride) can prevent relapse in people with schizophrenia. Participants who have had a recent hospitalization for schizophrenia and still have symptoms will receive KarXT or a placebo. The study mea…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo tested for long-term safety in teens with schizophrenia and kids with autism
Disease control Recruiting nowThis study is checking the long-term safety of a drug called KarXT in teenagers (13-17) with schizophrenia, and a combination of KarXT and KarX-EC in children (5-17) with irritability linked to autism. About 400 participants who completed earlier studies will take the drug for up…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Hope for Alzheimer's psychosis: new drug aims to stop relapses
Disease control Recruiting nowThis study tests an investigational drug called KarXT to see if it can prevent the return of psychosis (like hallucinations or delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can Anti-Nausea meds tame KarXT's stomach woes?
Symptom relief Recruiting nowThis study tests whether taking anti-nausea medication alongside KarXT—a drug used for schizophrenia—can reduce nausea and vomiting. Healthy volunteers will take KarXT with either scheduled or as-needed antiemetics. The goal is to find a safer, more comfortable way to start treat…
Phase 4 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Could this pill ease Alzheimer's hallucinations?
Symptom relief Recruiting nowThis Phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a plac…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Hope for Alzheimer's psychosis: new drug KarXT enters final trial
Symptom relief Recruiting nowThis phase 3 trial tests whether the drug KarXT can safely reduce psychosis (hallucinations and delusions) in people with mild to severe Alzheimer's disease. About 406 participants aged 55 to 90 will receive either KarXT or a placebo. The study aims to see if the drug improves sy…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
New drug KarXT aims to safely treat Alzheimer's psychosis in Long-Term trial
Symptom relief Recruiting nowThis study is testing the long-term safety of an experimental drug called KarXT for people with Alzheimer's disease who also experience psychosis (hallucinations or delusions). About 800 participants who completed earlier studies will take KarXT for up to 52 weeks. The main goal …
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Gene type may change how KarXT works in your body
Knowledge-focused Recruiting nowThis early-stage study looks at how different versions of a liver enzyme (CYP2D6) affect the breakdown of xanomeline, one part of the drug KarXT. About 56 healthy volunteers with four different metabolism types will take KarXT and have their blood tested. The goal is to see if pe…
Phase 1 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC